Form 4: Apellis Director Sinclair Dunlop Receives Equity Grant

Apellis Pharmaceuticals director A. Sinclair Dunlop was granted restricted stock units and stock options, aligning his interests with shareholders.

Summary

• Director A. Sinclair Dunlop of Apellis Pharmaceuticals, Inc. received a grant of 7,961 restricted stock units (RSUs) and 14,684 stock options on January 1, 2026.
• The RSUs were granted at a price of $0 and will fully vest on January 1, 2027, contingent on his continued service as a director.
• The stock options have an exercise price of $25.12 and will vest quarterly from the grant date, expiring on December 31, 2033.
• Following these transactions, Mr. Dunlop beneficially owns 161,567 shares of common stock and 14,684 stock options.

Sentiment

Score: 6

Explanation: The filing reports a routine equity grant to a director, which is a neutral to slightly positive event as it aligns director interests with shareholders, but also involves minor dilution.

Positives

• The grant of restricted stock units and stock options to Director A. Sinclair Dunlop aligns his financial interests with those of Apellis Pharmaceuticals' shareholders.
• Equity compensation is a standard practice to incentivize long-term commitment and performance from directors.

Negatives

• The issuance of new equity awards could lead to minor dilution for existing shareholders, though this is a standard component of executive and director compensation.

Future Outlook

The restricted stock units are set to fully vest on January 1, 2027, subject to continued service. The stock options will vest quarterly from the grant date, subject to continued service, and expire on December 31, 2033.

Industry Context

The grant of equity compensation, including restricted stock units and stock options, to a director is a common practice in the biotechnology and pharmaceutical industry. This approach is widely used to attract, retain, and motivate experienced board members by linking their compensation to the company's long-term performance and shareholder value creation.

Comparison to Industry Standards

• The structure of equity compensation, involving both restricted stock units and stock options with vesting schedules tied to continued service, is consistent with standard practices for director compensation in the pharmaceutical and biotechnology sectors.
• While specific comparable companies are not mentioned, this type of compensation package is typical for directors at publicly traded biopharmaceutical companies of similar size and stage to Apellis Pharmaceuticals, Inc., aiming to align director incentives with long-term shareholder value.

Related Party Transactions

• The equity grant to Director A. Sinclair Dunlop represents a transaction between the company and a related party (a director).

Stakeholder Impact

• Shareholders: Minor potential for dilution due to the issuance of new shares/options, but also improved alignment of director's interests with shareholder value.
• Employees: No direct impact mentioned.
• Customers: No direct impact mentioned.
• Suppliers: No direct impact mentioned.
• Creditors: No direct impact mentioned.

Next Steps

• The restricted stock units are scheduled to vest on January 1, 2027.
• The stock options will vest quarterly from January 1, 2026, until fully vested.

Key Dates

Recommendation

This Form 4 filing details a routine equity compensation grant to a director and does not contain information that would fundamentally alter the investment thesis for Apellis Pharmaceuticals. It's a standard corporate governance practice to align director incentives with shareholder interests. Therefore, a "hold" recommendation is appropriate, as this event alone is unlikely to drive significant price movement or change the long-term outlook.

Keywords

Apellis Pharmaceuticals, APLS, Form 4, Insider Transaction, Director Compensation, Restricted Stock Units, Stock Options, Equity Grant, Sinclair Dunlop